Mechanisms and Consequences of Defective E Prostanoid Receptor Signaling in AERD
AERD 中 E 类前列腺素受体信号传导缺陷的机制和后果
基本信息
- 批准号:8195747
- 负责人:
- 金额:$ 52.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-15 至 2016-06-30
- 项目状态:已结题
- 来源:
- 关键词:Adenylate CyclaseAgonistAllergensAllergicAnimal ModelArachidonate 5-LipoxygenaseArachidonic AcidsAspirinAsthmaAvidityBindingBlood PlateletsBlood specimenBreathingBronchoconstrictionCellsCharacteristicsCyclic AMPDefectDinoprostoneDiseaseDisease modelDoseEP4 receptorEffector CellEnzymesEpigenetic ProcessForced expiratory volume functionFrequenciesFunctional disorderGenerationsHomeostasisImmune responseIn VitroIndividualInflammationIntegrinsLeukocytesLeukotriene A4Leukotriene C4Leukotriene E4LeukotrienesLinkLungLung diseasesMediatingMediator of activation proteinMessenger RNAOrganP-SelectinParentsPathogenesisPathway interactionsPhasePlatelet ActivationPlayPneumoniaProductionProstaglandin E ReceptorProstaglandinsProteinsReceptor SignalingRelative (related person)RoleSELP geneSamplingSignal TransductionTestingTherapeuticTissuesVascular remodelingbasecysteinyl leukotriene receptorcysteinyl-leukotrieneeosinophilepigenetic variationgranulocytein vitro activityin vivomRNA Expressionneutrophilnovelperipheral bloodpreventprostaglandin EP2 receptorreceptorreceptor couplingreceptor expressionreceptor functionrespiratoryresponseurinary
项目摘要
This project tests the hypotheses that deficient EP2 receptor expression and function in platelets and
leukocytes alters homeostasis of the adenylyl cyclase/cyclic adenosine monophosphate (cAMP) pathway as
a disease-causing mechanism in aspirin exacerbated respiratory disease (AERD). Platelets are required for
granulocyte recruitment in animal models of pulmonary inflammation, binding to leukocytes via P-selectin
(CD62P) and facilitating integrin avidity. When bound to neutrophils, platelets can also form leukotriene
(LT)C4 (the parent of the cysteinly leukotrienes (cys-LTs)) from neutrophil-derived LTA4. We have
discovered that platelets from subjects with aspirin exacerbated respiratory disease (AERD) are markedly
deficient in expression of the Gs-linked EP2 receptor for PGE2 relative to platelets from normal and aspirin-tolerant
asthmatic (ATA) controls. As a result, neither exogenous PGE2 nor a selective EP2 agonist can
block activation of platelets from individuals with AERD in vitro, or the formation of platelet-leukocyte
aggregates. Moreover, peripheral blood samples from individuals with AERD contain several fold higher
frequencies of platelet-leukocyte aggregates than do samples from normal and aspirin-tolerant ATA controls,
suggesting a functional result of diminished EP2 signaling in vivo that could enhance both tissue
inflammation and the generation of cys-LTs. Furthermore, the defect in EP2 receptor expression extends to
peripheral blood leukocytes from individuals with AERD, accompanied by concomitantly defective expression
of mRNA encoding EP4 receptors; both defects are reversed by aspirin treatment. Aim 1 is to determine the
consequences of defects in the function of the EP2 subtype of prostaglandin E2 receptor on platelets in the
pathophysiology of AERD. Aim 2 is to determine the consequences of deficient of EP2 and EP4 receptor
signaling on 5-lipoxygenase (5-LO) pathway activity in peripheral blood leukocytes and whether the
deficiency is corrected by treatment with aspirin. Aim 3 is to characterize the extent of epigenetic variation in
EP receptors, classical and novel CysLTRs, and associated candidate effectors in AERD.
该项目测试了以下假说:缺乏EP2受体的表达和功能
白细胞改变腺苷环化酶/环磷酸腺苷(CAMP)途径的动态平衡
阿司匹林加重呼吸道疾病(AERD)的致病机制。血小板是人体必需的
肺炎症动物模型中粒细胞的募集,通过P-选择素与白细胞结合
(CD62p)和促进整合素亲和力。当血小板与中性粒细胞结合时,也会形成白三烯。
(Lt)C4(半胱氨酸白三烯(Cys-LTs)的母体)来自中性粒细胞来源的LTA4。我们有
发现患有阿司匹林加重呼吸道疾病(AERD)的受试者的血小板显著
与正常和阿司匹林耐受者的血小板相比,PGE2的Gs连锁EP2受体表达不足
哮喘(ATA)对照。因此,外源性PGE2和选择性EP2激动剂都不能
体外阻断AERD患者的血小板活化,或血小板-白细胞的形成
集合体。此外,AERD患者的外周血液样本中的AERD含量要高出几倍
血小板-白细胞聚集率高于正常和阿司匹林耐受性ATA对照组的样本,
提示体内EP2信号减弱的功能结果可能增强了这两个组织
炎症和Cys-LT的产生。此外,EP2受体表达的缺陷延伸到
AERD患者外周血白细胞伴有表达缺陷
编码EP4受体的信使核糖核酸;这两种缺陷都可通过阿司匹林治疗而逆转。目标1是确定
前列腺素E_2受体EP2亚型功能缺陷对高血压病患者血小板功能的影响
AERD的病理生理学。目的2是确定EP2和EP4受体缺陷的后果
外周血白细胞中5-脂氧合酶(5-LO)途径活性的信号转导
缺乏症可以通过服用阿司匹林来纠正。目标3是描述表观遗传变异的程度。
AERD中的EP受体、经典的和新的CysLTRs以及相关的候选效应因子。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joshua A Boyce其他文献
Cysteinyl leukotrienes and uridine diphosphate induce cytokine generation by human mast cells through a cysLT1/cysLT3 receptor-dependent mechanism
- DOI:
10.1016/s0091-6749(02)81894-2 - 发表时间:
2002-01-01 - 期刊:
- 影响因子:
- 作者:
Elizabeth Anne Mellor;Heather Dipeitrantonio;K Frank Austen;Joshua A Boyce - 通讯作者:
Joshua A Boyce
Chemokine receptor 3 mobilizes to the surface of human mast cells in response to IgE-mediated activation and potentiates their generation of IL-13 and IL-4
- DOI:
10.1016/s0091-6749(02)81303-3 - 发表时间:
2002-01-01 - 期刊:
- 影响因子:
- 作者:
KS Price;EA Mellor;DS Friend;N De Jesus;Joshua A Boyce - 通讯作者:
Joshua A Boyce
Joshua A Boyce的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joshua A Boyce', 18)}}的其他基金
Control of Pulmonary Inflammation by Leukotriene E4
白三烯 E4 控制肺部炎症
- 批准号:
10468771 - 财政年份:2021
- 资助金额:
$ 52.16万 - 项目类别:
Control of Pulmonary Inflammation by Leukotriene E4
白三烯 E4 控制肺部炎症
- 批准号:
10296403 - 财政年份:2021
- 资助金额:
$ 52.16万 - 项目类别:
Control of Pulmonary Inflammation by Leukotriene E4
白三烯 E4 控制肺部炎症
- 批准号:
10666460 - 财政年份:2021
- 资助金额:
$ 52.16万 - 项目类别:
Influence of NSAIDs and AERD on the expression and function of ACE2 - implications for SARS-CoV2 severity
NSAID 和 AERD 对 ACE2 表达和功能的影响 - 对 SARS-CoV2 严重程度的影响
- 批准号:
10197400 - 财政年份:2020
- 资助金额:
$ 52.16万 - 项目类别:
CysLT and P2Y Receptors in Lung Inflammation
肺部炎症中的 CysLT 和 P2Y 受体
- 批准号:
10321255 - 财政年份:2018
- 资助金额:
$ 52.16万 - 项目类别:
CysLT and P2Y Receptors in Lung Inflammation
肺部炎症中的 CysLT 和 P2Y 受体
- 批准号:
10083690 - 财政年份:2018
- 资助金额:
$ 52.16万 - 项目类别:
Eicosanoid Networks in Aspirin Hypersensitivity
阿司匹林过敏中的类二十烷酸网络
- 批准号:
10296672 - 财政年份:2017
- 资助金额:
$ 52.16万 - 项目类别:
Eicosanoid Networks in Aspirin Hypersensitivity
阿司匹林过敏中的类二十烷酸网络
- 批准号:
10062848 - 财政年份:2017
- 资助金额:
$ 52.16万 - 项目类别:
Eicosanoid Networks in Aspirin Hypersensitivity
阿司匹林过敏中的类二十烷酸网络
- 批准号:
10517922 - 财政年份:2017
- 资助金额:
$ 52.16万 - 项目类别:
Characterization of a Novel Growth and Survival Factor for Human Mast Cells
人类肥大细胞新型生长和生存因子的表征
- 批准号:
8977481 - 财政年份:2014
- 资助金额:
$ 52.16万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 52.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 52.16万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 52.16万 - 项目类别:
Grant-in-Aid for Scientific Research (C)